| pubmed-article:12589646 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12589646 | lifeskim:mentions | umls-concept:C0333343 | lld:lifeskim |
| pubmed-article:12589646 | lifeskim:mentions | umls-concept:C0345967 | lld:lifeskim |
| pubmed-article:12589646 | lifeskim:mentions | umls-concept:C0013687 | lld:lifeskim |
| pubmed-article:12589646 | lifeskim:mentions | umls-concept:C1511876 | lld:lifeskim |
| pubmed-article:12589646 | lifeskim:mentions | umls-concept:C0525037 | lld:lifeskim |
| pubmed-article:12589646 | lifeskim:mentions | umls-concept:C1442161 | lld:lifeskim |
| pubmed-article:12589646 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:12589646 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12589646 | pubmed:dateCreated | 2003-2-17 | lld:pubmed |
| pubmed-article:12589646 | pubmed:abstractText | The distinction between benign reactive mesothelial cells and malignant mesothelial cells in serous effusions is difficult and has an unusually high false negative rate. Unfortunately, there are no generally accepted markers to distinguish between benign reactive and malignant mesothelial cells. Homozygous deletion of CDKN2A is frequent in mesothelioma (present in > 70% of tumors). Therefore, detection of CDKN2A deletion by fluorescence in situ hybridization (FISH) was evaluated as an ancillary test in the cytologic diagnosis of malignant mesothelioma. | lld:pubmed |
| pubmed-article:12589646 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12589646 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12589646 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12589646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12589646 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12589646 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:12589646 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:12589646 | pubmed:author | pubmed-author:LadanyiMarcM | lld:pubmed |
| pubmed-article:12589646 | pubmed:author | pubmed-author:ZakowskiMaure... | lld:pubmed |
| pubmed-article:12589646 | pubmed:author | pubmed-author:RuschValerie... | lld:pubmed |
| pubmed-article:12589646 | pubmed:author | pubmed-author:IlleiPeter... | lld:pubmed |
| pubmed-article:12589646 | pubmed:copyrightInfo | Copyright 2003 American Cancer Society. | lld:pubmed |
| pubmed-article:12589646 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12589646 | pubmed:day | 25 | lld:pubmed |
| pubmed-article:12589646 | pubmed:volume | 99 | lld:pubmed |
| pubmed-article:12589646 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12589646 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12589646 | pubmed:pagination | 51-6 | lld:pubmed |
| pubmed-article:12589646 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:meshHeading | pubmed-meshheading:12589646... | lld:pubmed |
| pubmed-article:12589646 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12589646 | pubmed:articleTitle | The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. | lld:pubmed |
| pubmed-article:12589646 | pubmed:affiliation | Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. | lld:pubmed |
| pubmed-article:12589646 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12589646 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12589646 | lld:pubmed |
